Replies to post #122791 on Biotech Values

[DewDiligence]

Warfarin a lot cheaper and PBMs can report to their business customers that their pharma costs have been effectively managed. Clearly does not take into effect cost of warfarin monitoring, etc.

You’re even more cynical than rph_in_wi about what motivates the PBMs. I didn’t think that was possible :- )

Do you have any idea why B-I has not sought to get Pradaxa approved in the US for the hip/knee indication?